DAMGO: Physiology and What Research Reports

What DAMGO Is

DAMGO is a short synthetic peptide — [D-Ala2, N-MePhe4, Gly-ol]-enkephalin — designed as a chemically stabilised analogue of the endogenous opioid peptide enkephalin. The substitutions that give it its name make it resistant to the peptidases that rapidly degrade natural enkephalins, and they push its binding strongly toward the mu-opioid receptor (MOR) rather than the delta or kappa subtypes. That selectivity is the entire reason the compound exists: it lets investigators activate one receptor class in isolation and attribute whatever follows to that receptor.

Unlike most entries in a physiology library, DAMGO is not something the body makes. It has no endogenous source, no circulating concentration and no physiological role of its own. What it does have is a well-characterised target. The mu-opioid receptor is a G-protein-coupled receptor expressed throughout the central and peripheral nervous system — in brainstem respiratory nuclei, hippocampus, striatum, cerebellum, spinal dorsal horn, nucleus accumbens and even the retina — and DAMGO is one of the standard pharmacological keys used to open it in experimental preparations. It is a laboratory reagent, supplied for research use only, and is not an approved drug in any jurisdiction.

This page is for educational purposes only and is not medical advice; consult a licensed physician for any health question. Nothing here describes a protocol, and every effect described below was measured in animal tissue or animal models, not in people.

Where the Mu-Opioid Receptor Sits in Physiology

Endogenous opioid peptides — enkephalins, endorphins, dynorphins — act as neuromodulators rather than fast transmitters. Mu-opioid receptor activation typically opens potassium channels and closes calcium channels, which hyperpolarises neurons and suppresses transmitter release from presynaptic terminals. Because the receptor sits on both excitatory and inhibitory neurons, the net effect of activating it depends entirely on which circuit is being examined. DAMGO studies are, in effect, a map of that dependence.

Breathing and the brainstem

The preBötzinger complex generates the inspiratory rhythm and expresses mu-opioid receptors densely. Researchers using organotypic slice cultures reported that mu-opioid receptor activation with DAMGO reduced glutamate release in the preBötzinger complex, identifying a presynaptic locus for opioid suppression of respiratory drive (PMID 36096669). A separate in vitro study of neonatal preparations reported that mu-opioid receptor activation transformed the respiratory motor pattern rather than simply silencing it, with the pattern change depending on mu-opioid receptor signalling (PMID 35936900). Together these reports are part of why opioid effects on breathing are studied at the level of network reconfiguration, not just rate suppression.

Hippocampus and network oscillations

In the hippocampus, mu-opioid receptors sit largely on inhibitory interneurons, so activating them disinhibits principal cells. A 2019 study reported that mu-opioid receptor activation modulated the phase-coupling of gamma oscillations between CA3 and CA1, altering how the two subfields coordinated their rhythms (PMID 30834352). This is a good illustration of the general point: the same receptor, activated in an inhibitory network, produces excitation at the population level.

Striatum and cerebellum

Researchers examining striatal low-threshold spike interneurons reported dichotomous effects of mu-opioid receptor activation, with the direction of response differing between cell populations rather than being uniform across the structure (PMID 29259544). In mouse cerebellar cortex, a 2022 study investigated the mechanisms underlying mu-opioid receptor effects on parallel fiber–Purkinje cell synaptic transmission, reporting modulation at that synapse (PMID 35546898).

Spinal cord and nociception

The spinal dorsal horn is the classical site of opioid analgesia. A study of mu-opioid receptor activation in the spinal dorsal horn examined its effect specifically on GABAergic neurons, reporting that the receptor's action on inhibitory cells is part of the local circuit picture (PMID 29962856). Work on pain modulation has also looked above the spinal cord: an experimental neurology study reported that the nucleus accumbens facilitates nociception, examining opioid signalling in that structure (PMID 21458450). A separate report on neuronal cytochrome P450 activity and opioid analgesia examined relevant sites and mechanisms by which P450 activity contributes to opioid antinociception (PMID 25935691).

Feeding, reward and sensory systems

Mu-opioid signalling in the nucleus accumbens has long been linked to the hedonic aspects of eating. Researchers reported that adenosine–opioid interaction in the nucleus accumbens mediated palatable food intake, using receptor-selective pharmacology to dissect the interaction (PMID 19822132). An older anesthesia study examined sugar solution analgesia and reported effects of glucose on expressed mu-opioid receptors, connecting a bedside observation in neonates to receptor-level pharmacology (PMID 15976207). Outside the classical opioid territory, a 2021 study reported that endogenous opioid signalling in the mouse retina modulated the pupillary light reflex (PMID 33429857).

How DAMGO Is Used and Measured

DAMGO appears almost exclusively in ex vivo and in vivo preparations, applied directly to tissue or microinjected into a discrete brain region. Typical readouts include:

• Whole-cell patch clamp — measuring evoked or spontaneous postsynaptic currents before and after application, as in the preBötzinger glutamate-release work (PMID 36096669).
• Extracellular field recording — capturing population rhythms such as hippocampal gamma (PMID 30834352).
• Motor-output recording — nerve root recordings of respiratory pattern in neonatal preparations (PMID 35936900).
• Behavioural assays after site-specific microinjection — food intake or nociceptive thresholds (PMID 19822132, PMID 21458450).
• Computational and structural modelling — molecular dynamics of receptor states, including a study that reported a biased activation mechanism induced by GPCR heterodimerisation in μOR/δOR dimers (PMID 36377848).

Selectivity is confirmed by reversal with mu-selective antagonists such as CTAP or naloxone, and by the absence of effect in mu-opioid receptor knockout tissue. Concentrations used in slice work are chosen by each laboratory from published concentration–response relationships; this page does not list them, and no dose here is offered as a protocol for anything.

Safety and Tolerability: What Studies Report

The verified literature summarised on this page consists of mechanistic animal and tissue studies. None of it was designed as a safety or tolerability trial in humans, and no human adverse-event data are reported in these papers. The physiological findings most relevant to risk are indirect: researchers reported that mu-opioid receptor activation reduced glutamate release in the preBötzinger complex (PMID 36096669) and transformed respiratory motor pattern in neonatal preparations in vitro (PMID 35936900) — findings that sit within the broader scientific effort to understand opioid-induced respiratory depression at the circuit level.

Why the Term Turns Up

Readers usually encounter "DAMGO" in the methods section of a neuroscience paper, in a figure legend, or in a review of opioid pharmacology. Its presence signals that the authors wanted to isolate mu-opioid receptor activation. It is not a peptide therapeutic, not a research chemical marketed for personal use, and not something with a human dosing literature. Understanding it as a selectivity tool is the fastest way to read the papers it appears in.

References

• Mu-opioid receptor-dependent transformation of respiratory motor pattern in neonates in vitro (Frontiers in Physiology, 2022)
• μ-Opioid receptor activation modulates CA3-to-CA1 gamma oscillation phase-coupling (IBRO Reports, 2019)
• µ-Opioid Receptor Activation Reduces Glutamate Release in the PreBötzinger Complex in Organotypic Slice Cultures (The Journal of Neuroscience, 2022)
• Dichotomous Effects of Mu Opioid Receptor Activation on Striatal Low-Threshold Spike Interneurons (Frontiers in Cellular Neuroscience, 2017)
• Neuronal cytochrome P450 activity and opioid analgesia: relevant sites and mechanisms (Brain Research, 2015)
• Mechanisms Underlying Mu Opioid Receptor Effects on Parallel Fiber-Purkinje Cell Synaptic Transmission in Mouse Cerebellar Cortex (Frontiers in Synaptic Neuroscience, 2022)
• Sugar solution analgesia: the effects of glucose on expressed mu opioid receptors (Anesthesia and Analgesia, 2005)
• The effect of µ-opioid receptor activation on GABAergic neurons in the spinal dorsal horn (Korean Journal of Physiology & Pharmacology, 2018)
• Endogenous Opioid Signaling in the Mouse Retina Modulates Pupillary Light Reflex (International Journal of Molecular Sciences, 2021)
• Nucleus accumbens facilitates nociception (Experimental Neurology, 2011)
• The role of nucleus accumbens adenosine-opioid interaction in mediating palatable food intake (Brain Research, 2010)
• Biased Activation Mechanism Induced by GPCR Heterodimerization: Observations from μOR/δOR Dimers (Journal of Chemical Information and Modeling, 2022)